Top Markets
Coin of the day
Colinz Laboratories Limited Colinz Laboratories Limited

Colinz Laboratories Limited

COLINZ
Rank in Stocks #36906
Colinz Laboratories Ltd. specializes in producing a diverse range of... Colinz Laboratories Ltd. specializes in producing a diverse range of pharmaceutical formulations, available in various dosage forms such as tablets, capsules, granules, oral liquids, injectables, ointments, and creams. The company's offerings target therapeutic areas including gynecology, cardiology, and gastroenterology, and span product categories like allopathy, ayurvedics, and nutraceuticals. Established on October 6, 1986, Colinz Laboratories is based in Mumbai, India.
Share Price
$0.88143552
Last synced: 2026-08-14
Market Cap
$2.22M
Change (1 day)
-4.06%
Change (1 year)
78.59%
Country
IN
Trade Colinz Laboratories Limited (COLINZ)

Category

P/E ratio for Colinz Laboratories Limited (COLINZ)
P/E ratio as of 2026 TTM: 0
According to Colinz Laboratories Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Colinz Laboratories Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.